Safety, Tolerability, and Pharmacokinetics of NorUrsodeoxycholic Acid (Shilpa Medicare Limited, India) in Healthy Adults: Results From a Phase I Open-Label Dose-Escalation Study
Trial Registration: Clinical Trials Registry-India: CTRI/2022/11/047561
Saved in:
| Main Authors: | Veerendra Kumar Panuganti, Chandrasekhar Varma Alluri, Mamatha Reddy Dundigalla, Javeed Mohammad, Pavan Kumar Madala, Sanyasirao K. S. S. V. V. |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-01-01
|
| Series: | Advances in Pharmacological and Pharmaceutical Sciences |
| Online Access: | http://dx.doi.org/10.1155/adpp/6613969 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
A riddle on norA, norB, and norC
by: Theresa Sievers, et al.
Published: (2025-02-01) -
Effect of Ursodeoxycholic Acid Alone Verses Ursodeoxycholic Acid and Rifampicin in Obstetric Cholestasis
by: Ayesha Amjad, et al.
Published: (2025-07-01) -
Ursodeoxycholic acid and hepatic diseases
by: G. V. Volynets, et al.
Published: (2021-06-01) -
Expression of norA, norB and norC efflux pump genes mediating fluoroquinolones resistance in MRSA isolates
by: Asmaa B Hamady, et al.
Published: (2024-03-01) -
Pseudorandom unitaries are neither real nor sparse nor noise-robust
by: Tobias Haug, et al.
Published: (2025-06-01)